案例分享

癌症研究中的转化代谢组学

发布日期:2016.02.14 浏览次数(458)

在过去的十年中,在引进新的验证癌症代谢生物标志物的临床实践上有一个瓶颈。不幸的是,早期发现的癌症并没有足够灵敏的生物标志物,并且监测治疗的癌症抗原仍然存在。新诊断学的需要导致了非靶向代谢组学对特定癌症的早期生物标志物的发现的探索以及靶向代谢组学用于研究肿瘤的发生发展机理。成功的转化策略将允许癌症治疗地早期干预,以提高生存率。我们的方法是用来实现这些目标的,以实现转化代谢组学在癌症方面取得进展。

这篇文章中使用的代谢组学技术谱领生物已开发成熟、完善,并对外提供服务,已为多位客户提供服务并获得好评。

 

癌症研究中的代谢组学_11.jpg

文献内容


Title:Translational metabolomics in cancer research.

Author:Nathaniel W Snyder,Clementina Mesaros & Ian A Blair

Journal: Biomark Med

Keywords: cancer、cancer diagnosis、diagnostic biomarkers、lipidomics、liquid chromatogr-aphy-mass spectrometry、NMR spectroscopy、prognostic biomarkers、untargeted metabolon-mics targeted metabolomics.

Abstract:
Over the last decade there has been a bottleneck in the introduction of new validated cancer metabolic biomarkers into clinical practice. Unfortunately, there are no biomarkers with adequate sensitivity for the early detection of cancer, and there remain a reliance on cancer antigens for monitoring treatment. The need for new diagnostics has led to the exploration of untargeted metabolomics for discovery of early biomarkers of specific cancers and targeted metabolomics to elucidate mechanistic aspects of tumor progression. The successful translation of such strategies to the treatment of cancer would allow earlier intervention to improve survival. We have reviewed the methodology that is being used to achieve these goals together with recent advances in implementing translational metabolomics in cancer.

点击打开文章下载链接

微信公众号或添加客服号